---
title: "Wegovy (semaglutide) in chronic weight management: Clinical trials questions"
description: "Clinical trials questions on Wegovy (semaglutide) in chronic weight management, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results and Pill vs injection. Questions: How much weight do people lose on Wegovy 2.4 mg (STEP 1)? Wegovy 2.4 mg: how many people lose 5%, 10%, 15%, or 20% of their weight? Wegovy in type 2 diabetes: how much weight do people lose (STEP 2)? Does Wegovy add weight loss to intensive behavioral therapy (STEP 3)? 13 further questions follow. 17 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Wegovy (semaglutide) in chronic weight management: Clinical trials questions

Manufacturer: Novo Nordisk Inc.  
Prescribing information: [Wegovy](https://www.novo-pi.com/wegovy.pdf)

Questions that apply to every indication of Wegovy are on [Wegovy (semaglutide), all indications](https://www.evicenter.com/medical-information/wegovy).

## Study results

<a id="wegovy-step1-weight-loss"></a>

### How much weight do people lose on Wegovy 2.4 mg (STEP 1)?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “STEP 1 was a 68-week randomized trial 
> that enrolled 1961 adult patients with 
> obesity or with overweight and at least 
> 1 weight-related comorbid condition; 
> patients with type 2 diabetes were 
> excluded.<sup>1</sup> Patients were randomized in a 
> 2:1 ratio to either Wegovy<sup>®</sup> 2.4 mg pen 
> (n=1306) or placebo (n=655) (with a 16-
> week dose escalation period), both in 
> conjunction with lifestyle intervention.<sup>1</sup>
> For 
> the 
> co-primary 
> end 
> points 
> (Figure 2), after 68 weeks, a statistically 
> significant reduction in body weight 
> was observed in patients treated with 
> Wegovy<sup>®</sup> pen (-14.9%) compared with 
> those treated with placebo (-2.4%). 
> A 
> greater 
> proportion 
> of 
> patients 
> achieved ≥5% weight reduction with 
> Wegovy<sup>®</sup> pen (83.5%) compared with 
> placebo (31.1%).<sup>1</sup> During the trial, 17% 
> of patients in the Wegovy<sup>®</sup> pen arm 
> discontinued 
> treatment 
> compared 
> with 22% in the placebo arm.<sup>7</sup> Changes 
> in 
> waist 
> circumference 
> and 
> select 
> cardiometabolic 
> parameters 
> were 
> evaluated as secondary end points 
> (Table 3).<sup>1</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 4, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=4)

> “Table 8. Changes in Body Weight at Week 68 in Studies 2, 3, and 4 with WEGOVY<sup>®</sup> 
> 2.4 mg Injection 
> Study 2
> (Obesity or 
> Overweight with 
> Comorbidity)
> Study 3
> (Type 2 Diabetes 
> with Obesity or 
> Overweight)
> Study 4
> (Obesity or 
> Overweight with 
> Comorbidity 
> Undergoing Intensive 
> Lifestyle Therapy)
> Intention-to-Treat1 PLACEBO
> N=655
> WEGOVY<sup>®</sup> 
> Injection 
> N=1,306
> PLACEBO
> N=403
> WEGOVY<sup>®</sup> 
> Injection 
> N=404
> PLACEBO
> N=204
> WEGOVY<sup>®</sup> 
> Injection 
> N=407
> Body Weight
> Baseline mean (kg)
> 105.2
> 105.4
> 100.5
> 99.9
> 103.7
> 106.9
> % change from 
> baseline (LSMean)
> -2.4
> -14.9
> -3.4
> -9.6 
> -5.7 
> -16
> % difference 
> from placebo 
> (LSMean) (95% CI)
> -12.4
> (-13.3; -11.6)*
> -6.2
> (-7.3; -5.2)*
> -10.3
> (-11.8; -8.7)*”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “<sup>1</sup> The intent-to-treat population includes all randomized patients. In Study 2, at Week 68, the body weight was missing 
> for 7.2% and 11.9% of patients randomized to WEGOVY<sup>®</sup> injection and placebo, respectively. In Study 3, at Week 68, the 
> body weight was missing for 4% and 6.7% of patients randomized to WEGOVY<sup>®</sup> injection and placebo, respectively. In 
> Study 4, at Week 68, the body weight was missing for 8.4% and 7.4% of patients randomized to WEGOVY<sup>®</sup> injection and 
> placebo, respectively. Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI).”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “* p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

Note: Study 2 of the Prescribing Information has the same design and enrollment (68 weeks, 1,961 patients randomized 2:1, type 2 diabetes excluded) as STEP 1 in the Clinical Product Review. Table 8 columns are placebo and WEGOVY injection for Study 2, then Study 3, then Study 4. Figure 2 of the Clinical Product Review gives the STEP 1 difference from placebo as -12.5%; Table 8 gives -12.4%.

<a id="wegovy-step-percent-achieving"></a>

### Wegovy 2.4 mg: how many people lose 5%, 10%, 15%, or 20% of their weight?

> “Table 8. Changes in Body Weight at Week 68 in Studies 2, 3, and 4 with WEGOVY<sup>®</sup> 
> 2.4 mg Injection 
> Study 2
> (Obesity or 
> Overweight with 
> Comorbidity)
> Study 3
> (Type 2 Diabetes 
> with Obesity or 
> Overweight)
> Study 4
> (Obesity or 
> Overweight with 
> Comorbidity 
> Undergoing Intensive 
> Lifestyle Therapy)
> Intention-to-Treat1 PLACEBO
> N=655
> WEGOVY<sup>®</sup> 
> Injection 
> N=1,306
> PLACEBO
> N=403
> WEGOVY<sup>®</sup> 
> Injection 
> N=404
> PLACEBO
> N=204
> WEGOVY<sup>®</sup> 
> Injection 
> N=407”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “% of Patients losing 
> greater than or equal 
> to 5% body weight
> 31.1
> 83.5
> 30.2
> 67.4
> 47.8
>  84.8
> % difference from 
> placebo (LSMean) 
> (95% CI)
> 52.4
> (48.1; 56.7)*
> 37.2
> (30.7; 43.8)*
> 37
> (28.9; 45.2)*
> % of Patients losing 
> greater than or equal 
> to 10% body weight
> 12
> 66.1
> 10.2
> 44.5
> 27.1
>  73
> % difference from 
> placebo (LSMean) 
> (95% CI)
> 54.1
> (50.4; 57.9)*
> 34.3
> (28.4; 40.2)*
> 45.9
> (38; 53.7)*
> % of Patients losing 
> greater than or equal 
> to 15% body weight
> 4.8
> 47.9
> 4.3
> 25.1
> 13.2
> 53.4
> % difference from 
> placebo (LSMean) 
> (95% CI)
> 43.1
> (39.8; 46.3)*
> 20.7
> (15.7; 25.8)*
> 40.2
> (33.1; 47.3)*
> % of Patients losing 
> greater than or equal 
> to 20% body weight<sup>2</sup>
> 1.7
> 30.2
> 2.3
> 12.8
> 3.5
> 33.9
> % difference from 
> placebo (LSMean) 
> (95% CI)<sup>2</sup>
> 28.6 
> (25,8; 31.3)
> 10.6
> (6.4; 14.7)
> 30.4
> (24.8; 36.1)”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “<sup>2</sup> Not included in the pre-specified hierarchical testing.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “* p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

Note: Each row gives placebo and WEGOVY injection for Study 2, then Study 3, then Study 4. Studies 2, 3, and 4 of the Prescribing Information have the same enrollment and design as STEP 1 (1,961 patients), STEP 2 (807 patients with type 2 diabetes), and STEP 3 (611 patients with intensive behavioral therapy) in the Clinical Product Review.

<a id="wegovy-step2-type-2-diabetes"></a>

### Wegovy in type 2 diabetes: how much weight do people lose (STEP 2)?

Applies to: Weight reduction in adults with overweight or obesity and type 2 diabetes

> “STEP 2 was a 68-week trial that enrolled 
> 807 patients with type 2 diabetes and 
> BMI ≥27 kg/m<sup>2</sup>. Patients included in the 
> trial had an A1c of 7% to 10% and were 
> treated with either diet and exercise 
> alone or 1 to 3 oral anti-diabetic drugs 
> (metformin, 
> sulfonylurea, 
> glitazone, 
> or 
> sodium-glucose 
> cotransporter 
> 2 
> inhibitor). Patients were randomized in 
> a 1:1 ratio to receive either Wegovy<sup>®</sup> 2.4 
> mg pen or placebo (with a 16-week dose 
> escalation period), both in conjunction 
> with lifestyle intervention.<sup>1</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 4, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=4)

> “For 
> the 
> co-primary 
> end 
> points 
> (Figure 2), after 68 weeks, a statistically 
> significant reduction in body weight 
> was observed in patients treated with 
> Wegovy<sup>®</sup> (semaglutide) injection 2.4 mg 
> (-9.6%) compared with those treated with 
> placebo (-3.4%). A greater proportion of 
> patients achieved ≥5% weight reduction 
> with Wegovy<sup>®</sup> pen (67.4%) compared 
> with placebo (30.2%).<sup>1</sup> During the trial, 
> 6.2% of patients in the Wegovy<sup>®</sup> 2.4 
> mg pen arm discontinued treatment 
> compared with 3.5% in the placebo 
> arm.<sup>17</sup> Changes in waist circumference 
> and select cardiometabolic parameters 
> were evaluated as secondary end points 
> (Table 3).<sup>1</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 6, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=6)

> “Administration of WEGOVY<sup>®</sup> injection resulted in less weight reduction in patients with type 2 diabetes 
> and obesity or overweight compared to those without type 2 diabetes and obesity or overweight [see 
> Clinical Studies (14.2)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

Note: The second passage is the STEP 2 results paragraph, which opens page 6 of the Clinical Product Review.

<a id="wegovy-step3-intensive-behavioral-therapy"></a>

### Does Wegovy add weight loss to intensive behavioral therapy (STEP 3)?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “STEP 3 was a 68-week trial that 
> enrolled 611 patients with obesity or 
> with overweight and at least 1 weight-
> related comorbid condition; patients 
> with type 2 diabetes were excluded.<sup>1</sup> 
> The patients were randomized in a 2:1 
> ratio to receive either Wegovy<sup>®</sup> 2.4 mg 
> pen (n=407) or placebo (n=204) (with 
> a 16-week dose escalation period) in 
> conjunction with intensive behavioral 
> therapy. Patients were provided with 
> 30 
> individual 
> intensive 
> behavioral 
> therapy visits with a registered dietitian. 
> Intensive behavioral therapy consisted 
> of an initial 8-week low-calorie diet 
> (1000-1200 kcal/day) followed by 60 
> weeks of a reduced calorie diet (1200-
> 1800 kcal/day) and increased physical 
> activity (100 minutes/week with gradual 
> increase to 200 minutes/week).<sup>1,9</sup>
> For the co-primary end points (Figure 
> 2), after 68 weeks, a statistically significant 
> reduction in body weight was observed 
> in patients treated with Wegovy<sup>®</sup> pen 
> (-16.0%) compared with those treated with 
> placebo (-5.7%). A greater proportion of 
> patients achieved ≥5% weight reduction 
> with Wegovy<sup>®</sup> pen (84.8%) compared 
> with placebo (47.8%).<sup>1</sup> During the trial, 
> 17% of patients in the Wegovy<sup>®</sup> pen arm 
> discontinued treatment compared with 
> 19% in the placebo arm.<sup>9</sup> Changes in waist 
> circumference and select cardiometabolic 
> parameters were evaluated as secondary 
> end points (Table 3).<sup>1</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 6, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=6)

<a id="wegovy-step4-weight-regain"></a>

### Do people regain weight after stopping Wegovy (STEP 4)?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “STEP 4 was a 68-week trial that 
> enrolled 902 patients with obesity or 
> with overweight and at least 1 weight-
> related comorbid condition; patients 
> with type 2 diabetes were excluded. After 
> a 20-week run-in period, during which 
> all patients received Wegovy<sup>®</sup> 2.4 mg 
> pen in addition to lifestyle intervention, 
> 803 patients were randomized in a 
> 2:1 ratio to continue Wegovy<sup>®</sup> 2.4 mg 
> pen (n=535) or placebo (n=268) for 48 
> weeks and both continued on lifestyle 
> intervention.<sup>1</sup>
> For the primary end point (Figure 3), 
> from randomization (week 20) to week 68, 
> treatment with Wegovy<sup>®</sup> pen resulted in a 
> statistically significant reduction in body 
> weight (-7.9%) compared with placebo 
> (+6.9%).<sup>1</sup> Changes in waist circumference 
> and select cardiometabolic parameters 
> were evaluated as secondary end points 
> (Table 3).<sup>1</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 6, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=6)

> “Trial product was permanently discontinued before randomization in 99 
> of 902 patients (11%); the most common reason was adverse reactions (n=48, 5.3%); 803 patients 
> reached WEGOVY<sup>®</sup> 2.4 mg injection and were then randomized in a 2:1 ratio to either continue on 
> WEGOVY<sup>®</sup> injection or receive placebo.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “Because patients 
> who discontinued WEGOVY<sup>®</sup> injection during titration and those who did not reach the 2.4 mg weekly 
> dose were not eligible for the randomized-treatment period, the results may not reflect the experience 
> of patients in the general population who are first starting WEGOVY<sup>®</sup> injection.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “% change from Week 20 at 
> Week 68 (LSMean)
> 6.9 
> -7.9
> % difference from placebo 
> (LSMean) (95% CI) 
> -14.8 
> (-16; -13.5)*”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “* p<0.001 (unadjusted 2-sided) for superiority, controlled for multiplicity.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “In Study 5, the proportions of patients who discontinued study drug were 5.8% and 
> 11.6% for WEGOVY<sup>®</sup> injection and placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “In medical studies, people who stopped taking Wegovy<sup>®</sup> generally regained weight.”

Source: [WEGOVY: Enhance Your Benefits Package with Wegovy® (semaglutide), captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/for-employers-payers.html#:~:text=In%20medical%20studies%2C%20people%20who,generally%20regained%20weight.)

Note: STEP 4 is a randomized withdrawal trial: only patients who reached the 2.4 mg dose during the 20-week run-in were randomized to continue Wegovy or switch to placebo. Study 5 of the Prescribing Information has the same design and enrollment (902 enrolled, 803 randomized after a 20-week run-in) as STEP 4 in the Clinical Product Review. In the Table 9 rows, the first value is placebo and the second is WEGOVY injection.

<a id="wegovy-step5-two-years"></a>

### How much weight do people lose on Wegovy 2.4 mg over 2 years (STEP 5)?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “STEP 5<sup>3</sup>: A 104-week trial of 304 adults with obesity (BMI ≥30 kg/m<sup>2</sup>) or overweight (BMI 27 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>) and ≥1 weight-related comorbidity, randomized 1:1 to Wegovy<sup>®</sup> 2.4 mg or placebo, both with a reduced-calorie diet and increased physical activity. Discontinuation rate: Wegovy<sup>®</sup>=13%, placebo=27%.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=primary%20analysis%20method-,STEP,placebo%3D27%25.)

> “15.2% vs 2.6% (~6 lb) mean weight loss with placebo at 2 years, for all patients in the trial regardless of whether patients stayed on treatment or used other weight-loss therapies”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=15.2%25%20vs%202.6%25%20%28~6%20lb%29,or%20used%20other%20weight%2Dloss%20therapies)

> “Treatment regimen estimand:
>
> This estimand is based on the intention-to-treat principle and was used as the primary analysis method”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=This%20estimand%20is%20based%20on%20the%20intention%2Dto%2Dtreat%20principle%20and%20was%20used%20as%20the%20primary%20analysis%20method,-STEP)

> “<sup>†</sup>Difference from placebo was -12.6%.<sup>3</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=from%20placebo%20was)

> “*p<0.0001 (unadjusted 2-sided) for superiority.<sup>3</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%2Ap%3C0.0001%20%28unadjusted%202%2Dsided%29%20for)

> “Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI).”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Missing%20data%20were%20imputed%20from,same%20randomized%20treatment%20arm%20%28RD%2DMI%29.)

> “16.7% vs 0.6% (~1.4 lb) mean weight loss with placebo at 2 years, in an idealized scenario estimating efficacy if all patients remained on treatment and used no other weight-loss therapies”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=16.7%25%20vs%200.6%25%20%28~1.4%20lb%29,used%20no%20other%20weight%2Dloss%20therapies)

> “This analysis was not included in the statistical testing hierarchy, and as such, is hypothetical and was not controlled for multiplicity”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=This%20analysis%20was%20not%20included%20in%20the%20statistical%20testing%20hierarchy%2C%20and%20as%20such%2C%20is%20hypothetical%20and%20was%20not%20controlled%20for%20multiplicity,-WeGoTogether%C2%AE%20Real%2DWorld%20Study)

> “A 
> greater proportion of patients achieved 
> ≥5% weight reduction with Wegovy<sup>®</sup> 
> pen (77.1%) compared with placebo 
> (34.4%). The proportions of patients 
> who achieved ≥5% weight reduction 
> are 
> observed 
> data, 
> which 
> include 
> only patients who had a body weight 
> assessment at week 104 (n=144 for 
> Wegovy<sup>®</sup> pen arm and n=128 for placebo 
> arm) and do not include all randomized 
> patients.<sup>3</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 6, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=6)

Note: STEP 5 results are from the chronic weight management page of the Wegovy HCP site and the Clinical Product Review, which cite Garvey et al., Nat Med 2022; the Wegovy Prescribing Information does not describe this trial.

<a id="wegovy-step6-east-asian-adults"></a>

### How much weight do East Asian adults lose on Wegovy (STEP 6)?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “STEP 6 was a 68-week randomized 
> trial that enrolled 401 East Asian adult 
> patients (Japan and South Korea) with 
> BMI ≥35 kg/m<sup>2</sup> and at least 1 weight-
> related comorbid condition or with a BMI 
> of 27 kg/m<sup>2</sup> to 34.9 kg/m<sup>2</sup> and at least 2 
> weight-related 
> comorbid 
> conditions. 
> Patients were randomized in a 2:1:1 
> ratio to either Wegovy<sup>®</sup> (semaglutide) 
> injection 2.4 mg (n=199), Wegovy<sup>®</sup> 1.7 
> mg pen (n=101), or placebo (n=101), all in 
> conjunction with lifestyle intervention.<sup>1</sup>
> For 
> the 
> co-primary 
> end 
> points 
> (Figure 4), after 68 weeks, a statistically 
> significant reduction in body weight 
> was observed in patients treated with 
> Wegovy<sup>®</sup> 2.4 mg pen (-13.2%) and 
> Wegovy<sup>®</sup> 1.7 mg pen (-9.6%) compared 
> with those treated with placebo (-2.1%).<sup>1</sup> A 
> greater proportion of patients achieved 
> ≥5% weight reduction with Wegovy<sup>®</sup> 
> 2.4 mg pen (84.0%) and Wegovy<sup>®</sup> 1.7 
> mg pen (72.8%) compared with placebo 
> (19.4%).<sup>1</sup> During the trial, 7%, 8%, and 3% 
> of patients in the Wegovy<sup>®</sup> 2.4 mg pen, 
> Wegovy<sup>®</sup> 1.7 mg pen, and placebo arms 
> discontinued treatment, respectively.<sup>14</sup> 
> Changes in waist circumference and 
> select 
> cardiometabolic 
> parameters 
> were evaluated as secondary end points 
> (Table 4).<sup>1</sup>”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 8, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=8)

> “Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI). At baseline, 
> 24.7% of patients had type 2 diabetes.”

Source: [WEGOVY: wegovy-clinical-product-review.pdf, page 8, captured 2026-11-12](https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/obesity/product-information/resources/library/wegovy/resource-documents/wegovy-clinical-product-review.pdf#page=8)

<a id="wegovy-step-up-wegovy-hd"></a>

### How much weight do people lose on Wegovy HD 7.2 mg (STEP UP)?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “STEP UP<sup>1,2</sup>: A 72-week trial of 1,407 adults with obesity (BMI ≥30 kg/m<sup>2</sup>). Patients were randomized 5:1:1 to once-weekly Wegovy<sup>®</sup> HD injection 7.2 mg, Wegovy<sup>®</sup> injection 2.4 mg, or placebo in conjunction with a reduced-calorie diet and increased physical activity. Discontinuation rate: Wegovy<sup>®</sup> HD injection 7.2 mg=11.7%, Wegovy<sup>®</sup> injection 2.4 mg=11.9%, placebo=29.4%.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=estimated%20treatment%20difference.-,STEP,injection%202.4%20mg%3D11.9%25%2C%20placebo%3D29.4%25.)

> “18.8% vs 3.9% (~10 lb) mean weight loss with placebo at 72 weeks, for all patients in the trial regardless of whether patients stayed on treatment or used other weight-loss therapies*<sup>†</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=18.8%25%20vs%203.9%25%20%28~10%20lb%29,treatment%20or%20used%20other%20weight%2Dloss)

> “Percentage of patients achieving ≥5% weight loss at 72 weeks: 88.7% of patients with Wegovy<sup>®</sup> HD vs 38.3% with placebo<sup>†</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Percentage%20of%20patients%20achieving%20%E2%89%A55%25,HD%20vs%2038.3%25%20with)

> “Treatment regimen estimand:
>
> This estimand is based on the intention-to-treat principle and was used as the primary analysis method”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Treatment%20regimen%20estimand%3A,as%20the%20primary%20analysis%20method)

> “*Co-primary end point: % change in body weight for Wegovy<sup>®</sup> HD vs placebo; ETD (95% CI): -14.9 (-16.2; -13.6).”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%2ACo%2Dprimary%20end%20point%3A%20%25%20change,%2895%25%20CI%29%3A%20%2D14.9%20%28%2D16.2%3B%20%2D13.6%29.)

> “<sup>†</sup>p<0.0001 (unadjusted 2-sided) for superiority.<sup>1</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%28unadjusted%202%2Dsided%29%20for)

> “20.7% vs 2.4% (~6 lb) mean weight loss with placebo at 72 weeks, in an idealized scenario estimating efficacy if all patients remained on treatment and used no other weight-loss therapies<sup>§</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=20.7%25%20vs%202.4%25%20%28~6%20lb%29,and%20used%20no%20other%20weight%2Dloss)

> “Percentage of patients achieving ≥5% weight loss at 72 weeks: 93.2% of patients taking Wegovy<sup>®</sup> HD vs 35.7% with placebo<sup>2</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Co%2Dprimary%20end%20point%3A-,Percentage%20of%20patients%20achieving%20%E2%89%A55%25%20weight%20loss%20at%2072%20weeks%3A,HD%20vs%2035.7%25%20with)

> “This analysis was not included in the statistical testing hierarchy, and as such, is hypothetical and was not controlled for multiplicity”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=This%20analysis%20was%20not%20included,was%20not%20controlled%20for%20multiplicity)

Note: Wegovy HD is the 7.2 mg once-weekly dose of Wegovy injection. The first set of results is the treatment regimen estimand (all randomized patients) and the second the efficacy estimand (if all patients had stayed on treatment).

<a id="wegovy-7-2-mg-vs-2-4-mg"></a>

### Does Wegovy 7.2 mg cause more weight loss than Wegovy 2.4 mg?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “<sup>‡</sup>Confirmatory secondary end point: % change in body weight for Wegovy<sup>®</sup> HD vs Wegovy<sup>®</sup> 2.4 mg; ETD (95% CI): -3.3 (-4.9; -1.6).”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=secondary%20end%20point%3A%20%25%20change,%2895%25%20CI%29%3A%20%2D3.3%20%28%2D4.9%3B%20%2D1.6%29.)

> “Table 12. Changes in Body Weight at Week 72 in Studies 8 and 9 with WEGOVY<sup>®</sup> 7.2 mg Injection
> Study 8
> (Patients with obesity)
> Study 9
> (Type 2 diabetes with obesity)
> Intention-to-Treat<sup>1</sup>
> PLACEBO
> N=201
> WEGOVY<sup>®</sup> 
> 2.4 mg 
> Injection 
> N=201
> WEGOVY<sup>®</sup>
> 7.2 mg 
> Injection
> N=1005
> PLACEBO
> N=102
> WEGOVY<sup>®</sup> 
> 2.4 mg 
> Injection
> N=103
> WEGOVY<sup>®</sup>
> 7.2 mg 
> Injection
> N=307
> Body Weight
> Baseline mean (kg)
> 112.4
> 116.5
> 112.4
> 112.1
> 107
> 110.5
> % change from baseline (LSMean)<sup>a</sup>
> -3.9
> -15.5
> -18.8
> -3.8
> -10.4**
> -13.2
> % difference from placebo (LSMean) 
> (95% CI)
> -14.9 
> [-16.2; -13.6]*
> -9.4 
> [-11.0; -7.8]*
> Difference (%) from 2.4 mg [95% CI]
> -3.3 
> [-4.9; -1.6]*”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “* p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “** This endpoint was not included in the hierarchy testing and is only for informative purposes.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

Note: Table 12 columns are placebo, WEGOVY 2.4 mg, and WEGOVY 7.2 mg for Study 8 (patients with obesity), then the same three arms for Study 9 (type 2 diabetes with obesity). Study 8 has the same design and enrollment (72 weeks, 1,407 patients randomized 5:1:1) as STEP UP on the Wegovy HCP site.

<a id="wegovy-step-up-percent-achieving"></a>

### Wegovy HD: how many people lose 10%, 15%, 20%, or 25% of their weight?

Applies to: Weight reduction in adults with obesity with the 7.2 mg once-weekly dose (Wegovy HD)

> “With Wegovy<sup>®</sup> HD, ~1 in 3 patients achieved ≥25% weight loss<sup>2</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=in%20that%20study%2C-,With,3%20patients%20achieved%20%E2%89%A525%25%20weight)

> “Relevant confirmatory secondary end points<sup>1</sup>:
>
> ≥10% weight loss at 72 weeks: 79.8% with Wegovy<sup>®</sup> HD vs 20.3% with placebo<sup>¶</sup>
> ≥15% weight loss at 72 weeks: 63.8% with Wegovy<sup>®</sup> HD vs 7.5% with placebo<sup>¶</sup>
> ≥20% weight loss at 72 weeks: 45.5% with Wegovy<sup>®</sup> HD vs 2.8% with placebo<sup>¶</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Relevant%20confirmatory%20secondary%20end,HD%20vs%202.8%25%20with)

> “~1 in 3 (31.2%) patients achieved<sup>2¶#</sup>
>
> at 72 weeks with Wegovy<sup>®</sup> HD
> vs 0% of patients with placebo”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=~1%20in%203%20%2831.2%25%29%20patients,0%25%20of%20patients%20with%20placebo)

> “<sup>¶</sup>p<0.0001 (unadjusted 2-sided) for superiority.<sup>1</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%C2%B6p%3C0.0001%20%28unadjusted%202%2Dsided%29%20for%20superiority.1)

> “<sup>#</sup>Observed data include only patients who had a body-weight assessment at week 72 (950 of 1,005 for Wegovy<sup>®</sup> HD 7.2 mg injection arm and 171 of 201 for placebo arm) and do not include all randomized patients.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=data%20include%20only%20patients%20who,not%20include%20all%20randomized%20patients.)

Note: These are STEP UP results (Wegovy HD 7.2 mg vs placebo at 72 weeks in adults with obesity). The 10%, 15%, and 20% proportions are treatment regimen estimand results; the 25% proportions are observed data.

<a id="wegovy-7-2-mg-type-2-diabetes"></a>

### Wegovy 7.2 mg in type 2 diabetes: how much weight do people lose?

Applies to: Weight reduction in adults with overweight or obesity and type 2 diabetes

> “Study 9 was a 72-week trial that enrolled 512 patients with obesity and type 2 diabetes. Patients 
> included in the trial had HbA1c 7 to 10% and were treated with either: diet and exercise alone or 1 
> to 3 oral antidiabetic drugs (metformin, sulfonylurea, glitazone or sodium-glucose co-transporter 2 
> inhibitor). Patients were randomized in a 3:1:1 ratio to receive either WEGOVY<sup>®</sup> 7.2 mg, WEGOVY<sup>®</sup> 
> 2.4 mg or placebo once weekly. At baseline, the mean age was 56 years (range 19 to 79), 52% were 
> female, 84% were White, 6% were Asian and 9% were Black or African American. A total of 6% were 
> Hispanic or Latino ethnicity. Mean baseline body weight was 110.1 kg and mean BMI was 38.6 kg/m<sup>2</sup>.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

> “Table 12. Changes in Body Weight at Week 72 in Studies 8 and 9 with WEGOVY<sup>®</sup> 7.2 mg Injection
> Study 8
> (Patients with obesity)
> Study 9
> (Type 2 diabetes with obesity)
> Intention-to-Treat<sup>1</sup>
> PLACEBO
> N=201
> WEGOVY<sup>®</sup> 
> 2.4 mg 
> Injection 
> N=201
> WEGOVY<sup>®</sup>
> 7.2 mg 
> Injection
> N=1005
> PLACEBO
> N=102
> WEGOVY<sup>®</sup> 
> 2.4 mg 
> Injection
> N=103
> WEGOVY<sup>®</sup>
> 7.2 mg 
> Injection
> N=307
> Body Weight
> Baseline mean (kg)
> 112.4
> 116.5
> 112.4
> 112.1
> 107
> 110.5
> % change from baseline (LSMean)<sup>a</sup>
> -3.9
> -15.5
> -18.8
> -3.8
> -10.4**
> -13.2
> % difference from placebo (LSMean) 
> (95% CI)
> -14.9 
> [-16.2; -13.6]*
> -9.4 
> [-11.0; -7.8]*
> Difference (%) from 2.4 mg [95% CI]
> -3.3 
> [-4.9; -1.6]*”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “* p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “** This endpoint was not included in the hierarchy testing and is only for informative purposes.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “<sup>1</sup> The intent-to-treat population includes all randomized patients. In Study 8, at Week 72, the body weight was missing for 5.5%, 6.0% and 15.0% of patients 
> randomized to WEGOVY<sup>®</sup> 7.2 mg, WEGOVY<sup>®</sup> 2.4 mg and placebo, respectively. In Study 9, at Week 72, the body weight was missing for 5.2% and 6.9% of patients 
> randomized to WEGOVY<sup>®</sup> 7.2 mg and placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “<sup>a</sup> Model based estimates are based on an analysis of covariance (or logistic regression for the 5%, 10%, 15% or 20% achievement endpoints) including treatment 
> as a factor and baseline value as a covariate. Missing data were multiple imputed from retrieved subjects of the same randomized treatment arm (RD-MI) in Study 8 
> or all retrieved subjects regardless of treatment arm assignment in Study 9.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “In Study 9, 
> 5.5% of patients treated with WEGOVY<sup>®</sup> 7.2 mg and 2% patients treated with placebo permanently 
> discontinued treatment as a result of adverse reactions.”

Source: [WEGOVY: Prescribing information, page 10, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=10)

Note: In the Table 12 rows, the last three columns are Study 9: placebo, WEGOVY 2.4 mg, and WEGOVY 7.2 mg.

<a id="wegovy-pill-oasis4-weight-loss"></a>

### How much weight do people lose on the Wegovy pill (OASIS 4)?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “OASIS 4<sup>1,10</sup>: A 64-week trial of 307 adults with obesity (BMI ≥30 kg/m<sup>2</sup>) or overweight (BMI 27 kg/m<sup>2</sup>-29.9 kg/m<sup>2</sup>) and ≥1 weight-related comorbid condition, randomized 2:1 to once-daily Wegovy<sup>®</sup> 25 mg tablets or placebo, both in conjunction with a reduced-calorie diet and increased physical activity. Discontinuation rate: 18% Wegovy<sup>®</sup> pill, 25.5% placebo.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=drop%2Douts%20multiple%20imputation.-,OASIS,pill%2C%2025.5%25%20placebo.)

On the page, select: Pill

> “13.6% vs 2.4% (~6 lb) mean weight loss with placebo at 64 weeks, for all patients in the trial regardless of whether patients stayed on treatment or used other weight-loss therapies<sup>5</sup>*<sup>†</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=13.6%25%20vs%202.4%25%20%28~6%20lb%29,treatment%20or%20used%20other%20weight%2Dloss)

On the page, select: Pill

> “Patients who lost ≥5% at 64 weeks: 76.3% with Wegovy<sup>®</sup> vs 31.3% with placebo*”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Patients%20who%20lost%20%E2%89%A55%25%20at,vs%2031.3%25%20with%20placebo%2A)

On the page, select: Pill

> “Treatment regimen estimand:
>
> This estimand is based on the intention-to-treat principle and was used as the primary analysis method”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Treatment%20regimen%20estimand%3A,as%20the%20primary%20analysis%20method)

> “Missing data were imputed from retrieved subjects of the same randomized treatment arm (RD-MI).”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Missing%20data%20were%20imputed%20from,same%20randomized%20treatment%20arm%20%28RD%2DMI%29.)

> “*p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%2Ap%3C0.0001%20%28unadjusted%202%2Dsided%29%20for%20superiority.)

> “Changes in Body Weight at Week 64 in Study 7 with WEGOVY<sup>®</sup> 25 mg Tablets
> Study 7 (Obesity or overweight with Comorbidity)
> Intention-to-Treat<sup>1</sup>
> PLACEBO
> N=102
> WEGOVY<sup>®</sup> 25 mg Tablet
> N=205
> Body Weight
> Baseline mean (kg)
> 104.8
> 106.4
> % change from baseline (LSMean)<sup>3</sup>
> -2.4
> -13.6
> % difference from placebo (LSMean) (95% CI)<sup>3</sup>
> -11.2 [-13.6; -8.8]<sup>2</sup>”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “<sup>1</sup> The intent-to-treat population includes all randomized patients. In Study 7, at Week 64, the body weight was missing for 6.3% and 11.8% of patients randomized 
> to WEGOVY<sup>®</sup> tablets and placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “16.6% vs 2.7% (~6 lb) mean weight loss with placebo at 64 weeks, in an idealized scenario estimating efficacy if all patients remained on treatment and used no other weight-loss therapies”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=16.6%25%20vs%202.7%25%20%28~6%20lb%29,used%20no%20other%20weight%2Dloss%20therapies)

On the page, select: Pill

> “This analysis was not included in the statistical testing hierarchy, and as such, is hypothetical and was not controlled for multiplicity”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=This%20analysis%20was%20not%20included,was%20not%20controlled%20for%20multiplicity)

> “Wegovy<sup>®</sup> tablets have not been studied for weight reduction in adults with type 2 diabetes and obesity or overweight.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=tablets%20have%20not%20been%20studied,diabetes%20and%20obesity%20or%20overweight.)

On the page, select: Pill

Note: The Wegovy pill is Wegovy (semaglutide) 25 mg tablets taken once daily. Study 7 of the Prescribing Information has the same design and enrollment (64 weeks, 307 patients randomized 2:1) as OASIS 4. In the Table 11 rows, the first value is placebo and the second is WEGOVY 25 mg tablets.

<a id="wegovy-pill-percent-achieving"></a>

### Wegovy pill: how many people lose 10%, 15%, or 20% of their weight?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “>1 out of 4 (27.9%) patients achieved ≥20% weight loss with Wegovy<sup>®</sup> pill at 64 weeks<sup>1,10</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%3E1%20out%20of%204%20%2827.9%25%29,pill%20at%2064)

On the page, select: Pill

> “Confirmatory secondary end points<sup>1</sup>
>
> ≥10% weight loss:
> 59.8% Wegovy<sup>®</sup> vs 14.4% with placebo<sup>‡</sup>
>
> ≥15% weight loss:
> 47% Wegovy<sup>®</sup> vs 5.5% with placebo<sup>‡</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Confirmatory%20secondary%20end,vs%205.5%25%20with)

On the page, select: Pill

> “% of Patients losing greater than or equal to 20% body weight<sup>3</sup>
> 3.1
> 27.9
> % difference from placebo (LSMean) (95% CI)<sup>3</sup>
> 24.8 [17.7; 31.9]<sup>2</sup>”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “<sup>1</sup> The intent-to-treat population includes all randomized patients. In Study 7, at Week 64, the body weight was missing for 6.3% and 11.8% of patients randomized 
> to WEGOVY<sup>®</sup> tablets and placebo, respectively.”

Source: [WEGOVY: Prescribing information, page 11, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=11)

> “<sup>‡</sup>p<0.0001 (unadjusted 2-sided) for superiority.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%28unadjusted%202%2Dsided%29%20for%20superiority.,-In%20an%20additional)

On the page, select: Pill

Note: These are OASIS 4 results for Wegovy 25 mg tablets vs placebo at 64 weeks in adults with obesity, or with overweight and at least one weight-related comorbidity, without type 2 diabetes. In the Table 11 row from the Prescribing Information (Study 7), the first value is placebo and the second is WEGOVY 25 mg tablets.

<a id="wegovy-pill-oasis4-doses"></a>

### Were the Wegovy pill doses in OASIS 4 the approved doses?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “In OASIS 4, the doses used in escalation were 3 mg, 7 mg, and 14 mg. Each dose was taken once daily for 4 weeks. These doses are bioequivalent to 1.5 mg, 4 mg, and 9 mg, which are the commercially available, FDA-approved doses. The 25 mg dose was studied in OASIS 4 and is available as the maintenance dose.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=In%20OASIS%204%2C%20the%20doses,available%20as%20the%20maintenance%20dose.)

On the page, select: Pill

<a id="wegovy-time-to-work"></a>

### How long does Wegovy take to start working?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “People respond to medication, including Wegovy<sup>®</sup>, differently, so there is no set time when your patients can expect to see results with Wegovy<sup>®</sup>. Be sure to check in with your patients regarding their progress.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=People%20respond%20to%20medication%2C%20including,your%20patients%20regarding%20their%20progress.)

This passage is in a collapsed section of the page; select: How long does it take for Wegovy® pen to start working?

<a id="wegovy-blood-pressure-cholesterol"></a>

### Does Wegovy lower blood pressure, cholesterol, and triglycerides?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition

> “Confirmatory secondary end points:
> Change from baseline to week 104 in<sup>3</sup>:
>
> Waist circumference:
>
> 5.7-inch reduction
>
> 2-inch reduction with placebo
>
> Systolic blood pressure:
>
> 5.7 mm Hg reduction
>
> 1.6 mm Hg reduction with placebo
>
> Supportive secondary end points: Change from baseline to week 104 in<sup>3</sup>:
>
> Lipid profile:
>
> Total cholesterol
>
> 3.3% reduction
>
> 1.4% increase with placebo
>
> LDL
>
> 6.1% reduction
>
> 2.7% reduction with placebo
>
> HDL
>
> 9.6% increase
>
> 8.1% increase with placebo
>
> Triglycerides
>
> 19% reduction
>
> 3.7% increase with placebo
>
> Diastolic blood pressure:
>
> 4.4 mm Hg reduction
>
> 0.8 mm Hg reduction with placebo
>
> A1c:
>
> 0.4% reduction
>
> 0.1% reduction with placebo
>
> Safety end point: Change in<sup>3</sup>:
>
> Heart rate:
>
> 3.3 bpm increase 
>
> 0.8 bpm reduction with placebo”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Confirmatory%20secondary%20end%20points%3A,0.8%20bpm%20reduction%20with%20placebo)

> “Wegovy<sup>®</sup> is not indicated to treat hypertension, type 2 diabetes, or dyslipidemia.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=0.8%20bpm%20reduction%20with%20placebo-,Wegovy%C2%AE%20is%20not%20indicated%20to%20treat%20hypertension%2C%20type%202%20diabetes%2C%20or%20dyslipidemia.)

> “Supportive secondary end points were not included in the statistical testing hierarchy and, as such, not controlled for multiplicity.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=Supportive%20secondary%20end%20points%20were%20not%20included%20in%20the%20statistical,such%2C%20not%20controlled%20for%20multiplicity.)

Note: These values are STEP 5 results for Wegovy 2.4 mg vs placebo from baseline to week 104 in adults with obesity, or with overweight and at least one weight-related comorbidity. STEP 5 is not described in the Wegovy Prescribing Information.

## Pill vs injection

<a id="wegovy-pill-vs-injection"></a>

### Is the Wegovy pill as effective as the Wegovy injection?

Applies to: Chronic weight management in adults with obesity, or with overweight and at least one weight-related comorbid condition, with Wegovy tablets (pill)

> “A direct comparison cannot be made between Wegovy<sup>®</sup> pill and injectable Wegovy<sup>®</sup>.<sup>1</sup>”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=A%20direct%20comparison%20cannot%20be,pill%20and%20injectable)

On the page, select: Pill, then How does oral Wegovy® compare with the injectable pen for weight loss?

> “Oral Wegovy<sup>®</sup> (a once-daily pill) and injectable Wegovy<sup>®</sup> (a once-weekly pen) both contain semaglutide and are both FDA approved to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight with at least 1 weight-related comorbidity; however, they differ in administration, absorption, dosage schedules, and storage requirements.”

Source: [WEGOVY: Chronic Weight Management Trial Results, captured 2026-11-12](https://www.novomedlink.com/obesity/products/treatments/wegovy/efficacy-safety/chronic-weight-management.html#:~:text=%28a%20once%2Ddaily%20pill%29%20and%20injectable,dosage%20schedules%2C%20and%20storage%20requirements.)

On the page, select: Pill, then How does oral Wegovy® compare with the injectable pen for weight loss?

> “In patients with overweight or obesity without type 2 diabetes, semaglutide concentrations following 
> once-daily administration of oral WEGOVY<sup>®</sup> 25 mg tablet are predicted to be comparable to WEGOVY<sup>®</sup> 
> 2.4 mg once-weekly injection, with higher variability in semaglutide concentrations compared to 
> subcutaneous administration (90% of patients had average concentrations between 27 and 186 nmol/L 
> with WEGOVY<sup>®</sup> 25 mg tablet versus 51 and 110 nmol/L with WEGOVY<sup>®</sup> 2.4 mg once-weekly injection).”

Source: [WEGOVY: Prescribing information, page 8, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=8)

> “Given the differences in average semaglutide blood concentrations after administration of WEGOVY<sup>®</sup> 
> tablets and WEGOVY<sup>®</sup> injection, and the higher variability in semaglutide blood concentrations after 
> administration of WEGOVY<sup>®</sup> tablets in all patient populations, some patients with type 2 diabetes 
> taking WEGOVY<sup>®</sup> tablets may experience subtherapeutic semaglutide blood concentrations. In 
> patients with type 2 diabetes with an inadequate response to WEGOVY<sup>®</sup> tablets, consider alternative 
> therapies, including switching to WEGOVY<sup>®</sup> injection [see Dosage and Administration (2.5)].”

Source: [WEGOVY: Prescribing information, page 7, captured 2026-11-12](https://www.novo-pi.com/wegovy.pdf#page=7)

## Related pages
- [Medical information: Wegovy (semaglutide): Chronic weight management](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management)
- [Indication](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/indication)
- [Safety](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/safety)
- [Specific populations](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/wegovy--chronic-weight-management/access-and-coverage)
